CymaBay Therapeutics, Inc.
CBAYNASDAQHealthcare
$32.48
+$0.01(+0.03%)
Market Cap$3.7B
P/E Ratio—
52W High$32.5
52W Low$7.261
CymaBay Therapeutics, Inc. (CBAY) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CBAY · earnings · updated Jun 8, 2026
Latest Earnings
Q1 FY2024Report Date: Feb 28, 2024EPS Actual
-$0.35
Est. -$0.32 · -9.4%
Revenue
$0.00B
Est. $0.00B · +42.5%
Fiscal Period
Q1 FY2024
FY ends December
Report Date
Feb 28, 2024
After Market Close
▼ Miss EPS▲ Beat Revenue
CBAY reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▼ Q1 FY2024 | Feb 28, 2024 | -$0.32 | -$0.35 | -9.4% | $0.00B | $0.00B | +42.5% |
| ▼ Q4 FY2023 | Nov 7, 2023 | -$0.30 | -$0.32 | -6.7% | — | $0.00B | — |
| ▲ Q3 FY2023 | Aug 10, 2023 | -$0.21 | -$0.01 | +95.2% | $0.03B | $0.01B | +213.3% |
| ▼ Q2 FY2023 | May 15, 2023 | -$0.16 | -$0.29 | -81.3% | — | $0.02B | — |
| — Q1 FY2023 | Mar 16, 2023 | -$0.30 | -$0.30 | +0.0% | — | — | — |
| ▲ Q4 FY2022 | Nov 14, 2022 | -$0.30 | -$0.28 | +6.7% | — | — | — |
| ▼ Q3 FY2022 | Aug 11, 2022 | -$0.30 | -$0.31 | -3.3% | — | — | — |
| ▼ Q2 FY2022 | May 12, 2022 | -$0.31 | -$0.32 | -3.2% | — | — | — |
Q1 FY2024
Feb 28, 2024Miss
EPS Actual
-$0.35
EPS Est.
-$0.32
EPS Surpr.
-9.4%
Revenue
$0.00B
Q4 FY2023
Nov 7, 2023Miss
EPS Actual
-$0.32
EPS Est.
-$0.30
EPS Surpr.
-6.7%
Revenue
—
Q3 FY2023
Aug 10, 2023Beat
EPS Actual
-$0.01
EPS Est.
-$0.21
EPS Surpr.
+95.2%
Revenue
$0.03B
Q2 FY2023
May 15, 2023Miss
EPS Actual
-$0.29
EPS Est.
-$0.16
EPS Surpr.
-81.3%
Revenue
—
Q1 FY2023
Mar 16, 2023
EPS Actual
-$0.30
EPS Est.
-$0.30
EPS Surpr.
+0.0%
Revenue
—
Q4 FY2022
Nov 14, 2022Beat
EPS Actual
-$0.28
EPS Est.
-$0.30
EPS Surpr.
+6.7%
Revenue
—
Q3 FY2022
Aug 11, 2022Miss
EPS Actual
-$0.31
EPS Est.
-$0.30
EPS Surpr.
-3.3%
Revenue
—
Q2 FY2022
May 12, 2022Miss
EPS Actual
-$0.32
EPS Est.
-$0.31
EPS Surpr.
-3.2%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.20 | $-0.20 | $-0.20 | 1 |
| Q3 FY2026 | $-0.01 | $-0.01 | $-0.01 | 1 |
| Q2 FY2026 | $-0.18 | $-0.18 | $-0.18 | 1 |
| Q1 FY2026 | $-0.38 | $-0.38 | $-0.38 | 1 |
| Q4 FY2025 | $-0.69 | $-0.69 | $-0.69 | 1 |
| Q3 FY2025 | $-0.53 | $-0.53 | $-0.53 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.1B | $0.1B | $0.1B | 3 |
| Q3 FY2026 | $0.1B | $0.1B | $0.1B | 2 |
| Q2 FY2026 | $0.1B | $0.1B | $0.1B | 2 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q1 FY2024 | Feb 28, 2024 | -9.4% | $32.32 | $32.27 | -0.15% |
| ▼ Q4 FY2023 | Nov 7, 2023 | -6.7% | $16.44 | $16.44 | +0.00% |
| ▲ Q3 FY2023 | Aug 10, 2023 | +95.2% | $12.63 | $12.96 | +2.61% |
| ▼ Q2 FY2023 | May 15, 2023 | -81.3% | $10.25 | $10.40 | +1.46% |
| ▲ Q1 FY2023 | Mar 16, 2023 | +0.0% | $9.07 | $9.14 | +0.77% |
| ▲ Q4 FY2022 | Nov 14, 2022 | +6.7% | $3.55 | $3.61 | +1.69% |
| ▼ Q3 FY2022 | Aug 11, 2022 | -3.3% | $4.16 | $3.74 | -10.10% |
| ▼ Q2 FY2022 | May 12, 2022 | -3.2% | $1.72 | $1.78 | +3.49% |
Q1 FY2024-0.15%
Report Date
Feb 28, 2024
EPS Beat/Miss
-9.4%
Price Before
$32.32
Price After
$32.27
Q4 FY2023+0.00%
Report Date
Nov 7, 2023
EPS Beat/Miss
-6.7%
Price Before
$16.44
Price After
$16.44
Q3 FY2023+2.61%
Report Date
Aug 10, 2023
EPS Beat/Miss
+95.2%
Price Before
$12.63
Price After
$12.96
Q2 FY2023+1.46%
Report Date
May 15, 2023
EPS Beat/Miss
-81.3%
Price Before
$10.25
Price After
$10.40
Q1 FY2023+0.77%
Report Date
Mar 16, 2023
EPS Beat/Miss
+0.0%
Price Before
$9.07
Price After
$9.14
Q4 FY2022+1.69%
Report Date
Nov 14, 2022
EPS Beat/Miss
+6.7%
Price Before
$3.55
Price After
$3.61
Q3 FY2022-10.10%
Report Date
Aug 11, 2022
EPS Beat/Miss
-3.3%
Price Before
$4.16
Price After
$3.74
Q2 FY2022+3.49%
Report Date
May 12, 2022
EPS Beat/Miss
-3.2%
Price Before
$1.72
Price After
$1.78
Avg Beat Reaction+1.69%
Avg Miss Reaction-1.06%
Beat Rate3 / 8 quarters
Largest Move-10.10% (Q3 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CBAY ends December
CymaBay Therapeutics, Inc. (CBAY) most recently reported earnings on February 28, 2024 for Q1 FY2024, posting EPS of $-0.35 — missing the analyst consensus of $-0.32 by -9.4%. The next CBAY earnings date is expected around September 1, 2026.
Each quarter, investors track CBAY earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CBAY revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CBAY's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CBAY earnings · 5 questionsCymaBay Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. CBAY typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CBAY historically reports after market close (AMC).
CBAY earnings datewhen is CBAY earningsCBAY next earnings datewhen does CBAY report earningsCBAY earnings calendar
▸ Source: FMP · CymaBay Therapeutics, Inc. SEC filings · US GAAP · CymaBay Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026